FDA Approves ZEVTERA — La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company secured FDA approval for ZEVTERA (ceftobiprole medocaril sodium), positioning itself in the IV antibiotic market to address resistant bacterial infections. Investors view the clearance as a positive catalyst for growth and valuation, offering a potential revenue stream in the high-stakes hospital setting.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day